Pharmaceutical company Sandoz Inc. is voluntarily recalling losartan potassium hydrochlorothiazide (Losartan), as the pills may contain an impurity, N-nitrosodiethylamine (NDEA).
Scroll down to continue reading
More news from KIRO 7
- 'Dozens' of underground heroin-injection sites operating now in King County
- Dozens displaced in Lacey apartment fire
- Shots fired at Airbnb rental in Seattle's Magnolia neighborhood
- Seattle Mayor, Chief highlight need for new police contract on West Seattle tour
- Do you have an investigative story tip? Send us an email at email@example.com
"This impurity, which is a substance that occurs naturally in certain foods, drinking water, air pollution and industrial processes, has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC)," agency officials wrote in the Nov. 8 news release.
The recall involves 100 milligram/25 milligram Losartan tablets with the lot number JB8912 and expiration date of June 2020. The affected product was not distributed prior to Oct. 8, 2018, according to the FDA.
The agency recently recalled two other blood pressure drugs for the impurity, irbesartan and valsartan. Those who take these hypertension medications should consult with a doctor or pharmacist before discontinuing use of the drug.
© 2019 Cox Media Group